Lacrimal Gland Cells, situated within the orbit of the eye, are instrumental in the production and secretion of tears, contributing to ocular surface health and visual comfort. Comprising both acinar and ductal cells, these glands produce a complex fluid containing water, electrolytes, proteins, and mucins, collectively forming the tear film. Acinar cells synthesize and release the aqueous component of tears, while ductal cells modify the composition by adding electrolytes. The tear film serves multiple functions, including lubrication, protection against microbial invasion, and maintenance of optical clarity. Lacrimal gland cells are regulated by neural and hormonal signals; sympathetic stimulation increases tear production, while parasympathetic activity promotes mucin secretion. Dysfunction of lacrimal gland cells can lead to dry eye syndrome, a common condition characterized by inadequate tear production. Autoimmune disorders, medications, or environmental factors may contribute to lacrimal gland dysfunction. Understanding the physiology of these cells is crucial for developing treatments for dry eye and other ocular surface disorders. Ongoing research explores innovative therapeutic approaches, including artificial tears, anti-inflammatory agents, and glandular stimulation, to enhance tear film function and alleviate ocular discomfort.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy